Rigel Pharma gives preliminary 2025 results update

Rigel Pharmaceuticals, Inc. filed a current report to note that it has provided investors with preliminary, unaudited estimates of its financial results for the fourth quarter and full fiscal year ended December 31, 2025.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Rigel Pharmaceuticals, Inc. filed a current report to note that it has provided investors with preliminary, unaudited estimates of its financial results for the fourth quarter and full fiscal year ended December 31, 2025. These estimates are based on currently available information and do not include all details needed for a complete picture of the company’s financial condition or operating results for that period.

The company also disclosed that it issued a press release titled “Rigel Provides Business Update and 2026 Outlook,” which is included as Exhibit 99.1. That release contains a broader business update and the company’s outlook for 2026, and is incorporated by reference into this report.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Rigel Pharmaceuticals (RIGL) report in this 8-K filing?

Rigel Pharmaceuticals reported that it has provided preliminary, unaudited estimates of its financial results for the fourth quarter and fiscal year ended December 31, 2025, and referenced a business update and 2026 outlook press release.

Are Rigel Pharmaceuticals’ 2025 results in this filing audited?

No. The company states that the fourth quarter and full-year 2025 figures are preliminary and unaudited estimates based on currently available information.

Which period’s results does Rigel Pharmaceuticals address in this 8-K?

The filing covers preliminary, unaudited estimated financial results for Rigel Pharmaceuticals’ fourth quarter and fiscal year ended December 31, 2025.

What additional information does Rigel Pharmaceuticals reference for investors?

Rigel references a press release titled “Rigel Provides Business Update and 2026 Outlook,” attached as Exhibit 99.1, which offers a broader business update and the company’s 2026 outlook.

Where can investors find Rigel Pharmaceuticals’ 2026 outlook details?

Details on the 2026 outlook are contained in the press release titled “Rigel Provides Business Update and 2026 Outlook,” which is attached to the filing as Exhibit 99.1 and incorporated by reference.

Does this 8-K include full financial statements for Rigel Pharmaceuticals?

No. The company explains that the preliminary estimates do not present all necessary information for a complete understanding of its financial condition or results of operations for the fourth quarter or full year 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/12/2026 - 08:15 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

RIGEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)


0-29889			94-3248524
(Commission File No.)			(IRS Employer Identification No.)

611 Gateway Boulevard Suite 900
South San Francisco, CA			94080
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: (650) 624-1100

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of Each Class

Trading

Symbol(s)

Name of Each Exchange on Which

Registered

Common Stock, par value $0.001 per share

RIGL

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

In connection with the press release described in Item 8.01 below, on January 12, 2026, Rigel Pharmaceuticals, Inc. (“Rigel”) provided, on a preliminary and unaudited basis, certain estimated financial results for its fourth quarter and fiscal year ended December 31, 2025. The preliminary estimates are based on currently available information and do not present all necessary information for a complete understanding of Rigel’s financial condition as of December 31, 2025 or Rigel’s results of operations for the fourth quarter or fiscal year ended December 31, 2025.

Item 8.01. Other Events.

On January 12, 2026, Rigel issued a press release titled “Rigel Provides Business Update and 2026 Outlook.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.


Exhibit						Description

99.1						Press Release, dated January 12, 2026, titled “Rigel Provides Business Update and 2026 Outlook."
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: January 12, 2026	RIGEL PHARMACEUTICALS, INC.

	By:	/s/ Raymond J. Furey
		Raymond J. Furey
		Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary

Source: View Original Filing on SEC EDGAR